Category - News

Developments

NICE recommends Rhythm’s IMCIVREE for treating obesity, controlling hunger

England’s National Institute for Health and Care Excellence (NICE) issued guidance that recommends Rhythm Pharmaceuticals’ (NASDAQ:RYTM) IMCIVREE as an option for treating obesity and controlling hunger caused by pro...

July 18, 2022

Markets

HCW starts Clene at buy; PT $16

H.C.Wainwright initiated coverage of Clene (NASDAQ:CLNN) with a “buy” rating and price target of $16. The stock closed at $4.50 on July 15. Clene is focused on the development of novel clean-surfaced nanotechnologies...

July 18, 2022

Markets

AGP starts MeaTech at buy; PT $11

Alliance Global Partners initiated coverage of MeaTech 3D (NASDAQ:MITC) with a “buy” rating and $11 price target. The stock closed at $3.55 on July 15. MeaTech is a cellular agriculture firm focused on developing human...

July 18, 2022

Markets

HCW starts Oyster Point Pharma at buy; PT $20

H.C. Wainwright launched coverage of Oyster Point Pharma (NASDAQ:OYST) with a “buy” rating and $20 price target. The stock closed at $4.43 on July 15. Oyster Point Pharma is a commercial stage biopharmaceutical company...

July 18, 2022

Markets

Research Capital downgrades Bellus Health on valuation, financing

Research Capital downgraded Bellus Health (NASDAQ:BLU) to “hold” from “speculative buy” and removed its previous $14.50 price target so “we can properly account for the new dilution” from a $153-million offering of new...

July 14, 2022

Markets

Analysts downgrade ContraFect after DSMB urges Phase 3 MRSA trial end

Analysts for SVB Securities and Maxim Group downgraded ContraFect (NASDAQ:CFRX) after a data safety monitoring board recommended termination for futility of a Phase 3 trial evaluating exebacase in methicillin-resistant...

July 14, 2022

Markets

Dawson James cuts Pluristem to neutral after Phase 3 miss

Dawson James downgraded Pluristem Therapeutics (NASDAQ:PSTI) to “neutral” from “buy” and removed its price target after a Phase 3 trial investigating muscle regeneration following hip surgery did not meet the primary...

July 14, 2022

Developments

Soricimed Biopharma receives additional investment from NBIF

Closely-held Soricimed Biopharma closed a $200,000 investment from the New Brunswick Investment Fund (NBIF) to continue developing its investigational SOR-13 oncology drug candidate. “We are grateful to NBIF for their...

July 13, 2022

Markets

Cantor cuts Humanigen to neutral; PT to $2

Cantor Fitzgerald downgraded Humanigen (NASDAQ:HGEN) to “neutral” from “overweight” and slashed its price target to $2 from $30 after a failed COVID-19 study. The stock closed at $2.99 on July 12. The National Institute...

July 13, 2022

Markets

Stifel cuts Atara Biotherapeutics to hold; PT to $5

Stifel downgraded Atara Biotherapeutics (NASDAQ:ATRA) to “hold” from “buy” and lowered its price target to $5 from $16, following the company’s interim Phase 2 analysis with ATA188 for the treatment of multiple...

July 13, 2022

Category - News

Subscribe